PURPOSE: To assess the safety and efficacy of a second generation, anterior chamber phakic intraocular lens (Baikoff Model ZB5M) in patients with high myopia. METHODS: One hundred and twenty-one patients (134 eyes) with myopia of -7.00 to -18.80 D were implanted with the ZB5M lens and followed for 18 to 52 months; the number of eyes evaluated was: 6 months (104 eyes), 1 year (91 eyes), 18 months (78 eyes), 2 years (68 eyes), and 3 years (35 eyes). RESULTS: Postoperative spherical equivalent refraction averaged -1.00 D and the error in refractive correction (achieved minus intended) averaged -0.40 D during the first 2 years, increasing -to -1.30 D refraction and -0.60 D error in refractive correction at 3 years. At 2 years, approximately 40% of eyes had a spherical equivalent refraction within +/-0.50 D, and 65% within +/-1.00 D. The uncorrected distance visual acuity was 0.048 at baseline and 0.5 at 3 years; near visual acuity was 0.21 at baseline and approximately 0.7 over the 3 years of follow-up. Spectacle-corrected distance visual acuity at baseline was 0.54; it improved to 0.7. Near visual acuity was 0.65 at baseline and it improved to approximately 0.75. Endothelial cell counts in the central and peripheral cornea were reduced by an average 3.3% at 6 months, declining an additional 1% to 2% over the remaining follow-up period. Regression analyses indicated that most of the endothelial cell loss was due to surgery. Additional complications included halos/glare in 37 of 133 eyes (27.8%) and iris retraction with pupillary ovalization in 30 of 133 eyes (22.6%). The intraocular lens was exchanged in four of 133 eyes (3.0%) and removed in three of 133 eyes (2.3%), the latter because of halos (one eye) and a flat anterior chamber with severe inflammation (two eyes). CONCLUSIONS: Implantation of the Baikoff ZB5M lens in the anterior chamber of phakic eyes significantly reduced high myopia and produced a stable refractive outcome over the 3 years, accompanied by marked improvement in uncorrected distance visual acuity and minimal, non-progressive damage to the corneal endothelium. Frequent complications included pupillary ovalization and halos/glare. Improvements in accuracy of IOL power calculations are needed.

Adult↗

PubMedDate not supplied

[Etiological diagnosis of uveitis and therapeutic management].

Explore the source record for details and available documents.

Adrenal Cortex Hormones↗

PubMedDate not supplied

[Corneal transplantation and histocompatibility of the HLA system].

The HLA antigens appear to be involved in the rejection of corneal allografts. A relationship exist between HLA compatibility and the corneal rejection-free transplant survival. Eleven corneal transplants are performed on the basis of the best available HLA A and B match. Rejection-free transplant in this group is compared to a control group. The estimate rejection-free survival is 82%.

Corneal Diseases↗

PubMedDate not supplied

[HLA antigen expression of human cornea. Effect of organ culture preservation].

The aim of this study is to examine the variation of HLA expression on organ-cultured human corneas. Using an indirect immunofluorescence technique and monoclonal antibodies anti-HLA-A, B, C and anti-HLA-DR histocompatibility antigens were detected. In fresh corneas class I antigens were detected on epithelium and stroma but not on endothelium. Class II antigens were not detected on any corneal layer but were present on Langerhans cells within epithelium and stroma. The expression of HLA-A, B, C antigens within the corneal epithelium and the corneal stroma was not altered by 28 days of organ culture. HLA-DR antigens were present on Langerhans cells on corneas that had been in organ culture up to 14 days (present 6/9). After 14-28 days in culture Langerhans cells were not found on most corneas (present 3/12). Corneal preservation in organ culture at 31 degrees C affects expression of HLA antigens particularly of HLA-DR antigens. Combination of HLA matching donor-recipient with an 10-15 days organ cultured corneal button in high-risk patients seems to be of interest.

Cornea↗

PubMedDate not supplied

[Advances in the medical treatment of bacterial endophthalmitis].

Currently, the systemic antibiotics intraocular penetration's rate is low and we have to perform intraocular antibiotics injections to reach levels above the minimal inhibitory concentration of the bacterial agents found commonly in endophthalmitis. Authors try to specify a rational strategy based on pharmacokinetics and bacteriological aspects of a new class of antibiotics, the fluoroquinolones, using their own studies and those from other teams about the intraocular distribution of these antibiotics. Further investigation is mandatory to assess the safety and efficacy of our first clinical results.

4-Quinolones↗